CN1260718A - Antithelmintic compositions - Google Patents
Antithelmintic compositions Download PDFInfo
- Publication number
- CN1260718A CN1260718A CN98806135A CN98806135A CN1260718A CN 1260718 A CN1260718 A CN 1260718A CN 98806135 A CN98806135 A CN 98806135A CN 98806135 A CN98806135 A CN 98806135A CN 1260718 A CN1260718 A CN 1260718A
- Authority
- CN
- China
- Prior art keywords
- compositions
- salt
- niclosamide
- solvent
- dissolved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 claims abstract description 55
- 229960001920 niclosamide Drugs 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 30
- 239000002904 solvent Substances 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000003513 alkali Substances 0.000 claims description 8
- 238000004090 dissolution Methods 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 238000011065 in-situ storage Methods 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims description 3
- -1 alkali metal salt Chemical class 0.000 claims description 3
- 229960001614 levamisole Drugs 0.000 claims description 3
- 229910052755 nonmetal Inorganic materials 0.000 claims description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 claims description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001447 alkali salts Chemical class 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 239000003495 polar organic solvent Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000507 anthelmentic effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 230000000968 intestinal effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 208000025011 Distomatosis Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 241000252983 Caecum Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001137879 Moniezia expansa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000935974 Paralichthys dentatus Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001136 anti-cestodal effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000590 parasiticidal effect Effects 0.000 description 1
- 239000002297 parasiticide Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229950000975 salicylanilide Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
Abstract
The present invention relates to anthelmintic compositions containing niclosamide or a salt thereof as active ingredient, and methods to form such compositions.
Description
The present invention relates to Antithelmintic compositions.More specifically say, the present invention relates to contain the Antithelmintic compositions of niclosamide as active component.
Niclosamide (2 ', 5-two chloro-4 '-nitro N-phenylsalicylamide) is the known vermifuge that Bayer (Pty) Ltd. sells, and its commodity are called " Lintex ".Known niclosamide compositions is to exist with niclosamide form of suspension in liquid medium.Usually, give animal as the preparation of 20% (g niclosamide/100ml carrier) with the close rate of every 4kg body weight 1ml, particularly give sheep, can be used for controlling cestode and/or taper trematodiasis (Conical Fluke) and infect these suspensions.
Nurtaeva, K.S., Bekhill, A.F. and Vorobeva, Z.G. has reported the research about various niclosamide salt parasiticide effects in 1973 MedParazitol (Mosk) 42:86.Sodium salt demonstrates good activity.This test compound be with the form of mixtures of 5% starch or in water the form of suspension provide.
Summary of the invention
Now be surprisingly found out that,, can prevent and treat cestode and/or taper fluke infection effectively with the niclosamide that significantly reduces close rate on the surface so if give niclosamide with present composition form.
The invention provides the Antithelmintic compositions of solution form, it comprises, and the pharmacology goes up acceptable organic solvent and the pharmacology goes up the acceptable salt that is dissolved in the niclosamide in the organic solvent.
Organic solvent can comprise polar organic solvent and preferably this solvent be selected from propylene glycol; Glycerol; Polyethylene Glycol; Glycofurol; Isopropyl alcohol; The 2-pyrrolidine; The mixture of 2-pyrrolidin derivatives and these solvents.In a specific embodiments of the present invention, described solvent comprises the mixture of propylene glycol and glycerol, preferred 1: 1 (volume: ratio volume).In another specific embodiments of the present invention, described solvent can comprise propylene glycol.
In a specific embodiments of the present invention, niclosamide salt can comprise non-metal salt.In a preferred specific embodiments of the present invention, this salt comprises the meglumine salt of niclosamide.Other non-metal salt of niclosamide such as piperazine salt and ethanolamine salt are known.
In another specific embodiments of the present invention, niclosamide salt can comprise slaine.Described slaine can comprise pink salt.Yet preferably, described salt comprises the slaine that is selected from alkali metal salt and alkali salt.In the preferred specific embodiments of the present invention, described slaine comprises the niclosamide sodium salt.
Preferably, in situ preparation is dissolved in the salt of the niclosamide in the organic solvent.Can in described solvent and with niclosamide, be added to by the alkali dissolution that will be applicable to the preparation niclosamide salt and obtain this salt in this solvent.Preferably, at first, alkali dissolution in described solvent, is added niclosamide subsequently.Can stir and/or heat to help compound dissolution in described solvent.Also this solution can be filtered.
In a preferred specific embodiments of the present invention, dissolution of sodium hydroxide in described solvent, is added to niclosamide in this solution then.Obtain stable solution by this method.
In addition, Antithelmintic compositions also can comprise other active component.This component can be used for enlarging the treatment spectrum of said preparation.
Therefore, for example, described compositions can comprise or as alkali or as halogen acid salt example hydrochloric acid salt or as phosphatic levamisole active component as a supplement, make that resulting combination preparation can anti-effectively cestode and taper fluke infection (owing to having niclosamide) and anti-ascarid, because known levamisole is that anti-ascarid is effective.
Antioxidant also can be included in this solution and preferably add when alkali being added in the described solvent.Antioxidant can comprise sodium pyrosulfite.
Also can use other suitable adjuvant such as antiseptic and flavoring agent.
The present composition can be used as for animals or the human vermifuge.It can give by oral (with liquid or the liquid form in capsule or in order to granule or tablet form with above-mentioned formulations prepared from solutions).
The present invention provides a kind of method for preparing the Antithelmintic compositions of solution form on the other hand, and it comprises
-provide the pharmacology to go up acceptable solvent; With
-go up the acceptable niclosamide salt that is dissolved in the described solvent by forming the pharmacology, niclosamide is dissolved in the described solvent.
Can niclosamide be dissolved in the described solvent by providing the pharmacology to go up acceptable niclosamide salt and described salt being dissolved in the described organic solvent.
In addition preferably, the soluble niclosamide salt of in situ preparation.Preferably, the soluble niclosamide salt of in situ preparation as mentioned above.
Preferably, under anhydrous condition, implement this method.
Further specify the present invention by embodiment now, but therefore do not limit the present invention in the explanation scope of embodiments.
Embodiment 1
Propylene glycol is the niclosamide sodium solution of solvent
Under agitation, the sodium pyrosulfite that (promptly Powdered) NaOH that 0.5g was ground and 0.1g ground is dissolved in the 100ml propylene glycol.
Be necessary propylene glycol is slightly heated so that help the dissolving of these materials.Under agitation, in this solution, add the anhydrous niclosamide of 4g Powdered (by 80 mesh sieves) lentamente, form (g niclosamide/100ml propylene glycol) niclosamide solution of 4% until dissolving.In the resulting solution filtration and the air-tight bottle of packing into.Carefully water is not brought in this solution, because can cause end-product rotten like this, its rotten sign is that original clear solutions becomes pale brown color.
By testing this solution with 4% the solution mode of its anti-cestode of preliminary test and taper fluke infection effect on one's body the lamb.PRELIMINARY RESULTS shows, a small amount of niclosamide solution of the present invention is effective equally with the niclosamide that provides with conventional niclosamide form of suspension in a large number.
Embodiment 2
The oral Yomesan efficacy assessment that Buddhist nun cestode (Moniezia expansa) is covered in the anti-natural infection that had confirmed already in the lamb body
Under various close rates, measure the present invention's 4% niclosamide solution (" trial target ") press the preparation of embodiment 1 method and the effect of Yomesan (" standard substance ") the control illiteracy Buddhist nun cestode of 20% (g niclosamide/100ml carrier) form of suspension of obtaining by the commercial channel.Give standard substance with specified close rate 50mg/kg.This test is on applicant's farm, and carry out on " Rondebult " farm that promptly is positioned at Bapsfontein district, South Africa.Cover Buddhist nun cestode ingesta and painted mensuration and identify at laboratory.In this test, use about 2 months Dorper sheep.In process of the test, with these Yang Guan in pinfold and the water of feeding Herba Medicaginis and connecing from faucet.
The precondition of test is, with confirming to be carried out the teniacide test by the sheep of natural infection already.Can easily diagnose the illiteracy Buddhist nun cestode in the living animal.Diagnose with avette attitude and excretory strobilus, may have corresponding evaluation difficulty although be appreciated that these.Critical according to falling in a swoon (staggered critical) controlled trial is carried out this test.
With the animal grouping and in each group, in for three days on end, some animals are treated with trial target (various close rate), and some animals are with the not treatment control animal (" reference substance ") of making comparisons with standard substance (the prescribed dose rate is 50mg/kg) treatment and some animals.
In 3 days after test the previous day and test, give feces collecting bag on each dizzy lead for animal.The feces of collecting thus is used for measuring the strobilus of existence.
The animal that each is dizzy is in treatment execution in back 4 days and then carry out the following step:
1. the animal no pain is put to death (euthanase), peeling and the abdominal cavity is opened.Take out gastrointestinal tract and gather small intestinal and caecum/colon thus.With these labelling labelled notations with animal.
2. intestinal is placed in the bucket.Water is added in the two ends of this intestinal, every end is filled about 1-2 rice.
3. allow water flow through this intestinal until forming a loop in the bottom that is positioned at bucket from the two ends of intestinal.
4. an end of intestinal is loosened and, promote the water in the intestinal by this organ that slides lightly with finger.
5. this organ is cut off along its whole length direction with the internal organs shears, then, this intestinal wall is thoroughly washed with steam.After adding the formalin antiseptic, this intestinal is sealed in the glass jar.The purpose of doing like this is in case following test may need.
6. gather ingesta, by the flushing of Endecotts sieve and be stored in the glass jar, be used for laboratory directly in the sun, detect at vinyl disc.
The result is as follows:
| Animal mark mark | Medicine | Close rate | Infected animals is found in postmortem |
| ????7 | Trial target | ?????6mg/kg | ???????2 |
| ????7 | Trial target | ?????8mg/kg | ???????2 |
| ????7 | Trial target | ?????10mg/kg | ???????0 |
| ????5 | Trial target | ?????20mg/kg | ???????0 |
| ????3 | Trial target | ?????40mg/kg | ???????0 |
| ????9 | Standard substance | ?????50mg/kg | ???????0 |
| ????5 | Reference substance | ?????- | ???????5 |
The result shows, close rate is that the trial target of 10mg/kg chemical compound and standard substance that close rate is the 50mg/kg standard substance are effectively same.
Should be appreciated that the variation of a lot of details is possible, therefore this do not leave scope and spirit of the present invention.
Claims (24)
1. the Antithelmintic compositions of solution form, it comprises, and the pharmacology goes up acceptable organic solvent and the pharmacology goes up the acceptable salt that is dissolved in the niclosamide in this organic solvent.
2. the compositions of claim 1, wherein said organic solvent comprises polar organic solvent.
3. the compositions of claim 2, wherein said organic solvent is selected from propylene glycol; Glycerol; Polyethylene Glycol; Glycofurol; Isopropyl alcohol; The 2-pyrrolidine; The 2-pyrrolidin derivatives; Mixture with these solvents.
4. the compositions of claim 3, wherein said solvent comprises the mixture of propylene glycol and glycerol.
5. the compositions of claim 3, wherein said solvent comprises propylene glycol.
6. the compositions of above-mentioned arbitrary claim, the salt of wherein said niclosamide comprises non-metal salt.
7. the compositions of claim 6, wherein said salt comprises the meglumine salt of niclosamide.
8. each compositions of claim 1-5, the salt of wherein said niclosamide comprises slaine.
9. the compositions of claim 8, wherein said salt comprises the slaine that is selected from alkali metal salt and alkali salt.
10. the compositions of claim 9, wherein said slaine comprises the sodium salt of niclosamide.
11. the compositions of above-mentioned arbitrary claim, the wherein said salt that is dissolved in the niclosamide in the organic solvent is in situ preparation.
12. the compositions of claim 11, wherein said dissolved salt are to be added in this solvent in described solvent and with niclosamide by the alkali dissolution that will be applicable to the preparation niclosamide salt to prepare.
13. the compositions of claim 12 wherein at first also adds niclosamide with described alkali dissolution subsequently in described solvent.
14. the compositions of claim 10, wherein said dissolved sodium salt are by dissolution of sodium hydroxide is described in solvent, add then that niclosamide forms stable solution and in situ preparation.
15. aforesaid right requires each compositions, it also comprises at least a other active component.
16. the compositions of claim 15, it comprises or as alkali or as the levamisole of halogen acid salt.
17. aforesaid right requires each compositions, in described solution, it comprises antioxidant.
18. the compositions of claim 17, wherein said antioxidant comprises sodium pyrosulfite.
19. aforesaid right requires each compositions, it is the oral administration form.
20. the method for the Antithelmintic compositions of preparation solution form, it comprises
-provide the pharmacology to go up acceptable organic solvent; With
-go up the acceptable niclosamide salt that is dissolved in the described solvent by forming the pharmacology, niclosamide is dissolved in the described solvent.
21. the method for claim 20 wherein by providing the pharmacology to go up acceptable niclosamide salt and described salt being dissolved in the described organic solvent, is dissolved in niclosamide in the described solvent.
22. the method for claim 20 wherein is added to the dissolved niclosamide salt of in situ preparation in this solvent by the alkali dissolution that will be applicable to the preparation niclosamide salt in described solvent and with niclosamide.
23. Antithelmintic compositions with reference to appended embodiment solution form as described herein basically.
24. with reference to the appended embodiment method for preparing solution form Antithelmintic compositions as described herein basically.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA975154 | 1997-06-11 | ||
| ZA97/5154 | 1997-06-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1260718A true CN1260718A (en) | 2000-07-19 |
Family
ID=25586442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98806135A Pending CN1260718A (en) | 1997-06-11 | 1998-05-29 | Antithelmintic compositions |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0984783A1 (en) |
| JP (1) | JP2002511074A (en) |
| KR (1) | KR20010013139A (en) |
| CN (1) | CN1260718A (en) |
| AU (1) | AU8108698A (en) |
| BR (1) | BR9810433A (en) |
| CA (1) | CA2293683A1 (en) |
| WO (1) | WO1998056390A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1313438C (en) * | 2004-12-24 | 2007-05-02 | 仲恺农业技术学院 | Preparation method of snail killing agent crude medicine niclosamide |
| CN101601670B (en) * | 2009-06-30 | 2014-06-04 | 青岛蔚蓝生物股份有限公司 | Compound niclosamide parasite-expelling tablet used for pet and preparation method thereof |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005060951A2 (en) * | 2003-12-19 | 2005-07-07 | Bionaut Pharmaceuticals, Inc. | Anti-neoplastic agents, combination therapies and related methods |
| KR100692668B1 (en) * | 2005-05-27 | 2007-03-14 | 주식회사 에니텍시스 | a printed document feed apparatus |
| JP2017529393A (en) | 2014-09-12 | 2017-10-05 | アンティバイオティクス エーピーエスＡｎｔｉｂｉｏｔｘ Ａｐｓ | Antibacterial application of halogenated salicylanilide |
| GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
| KR102594716B1 (en) * | 2020-04-17 | 2023-10-27 | 영남대학교 산학협력단 | Composition for oral administration comprising niclosamide using self-nanoemulsifying drug delivery system and preparation method thereof |
| CN114948867A (en) * | 2022-07-22 | 2022-08-30 | 河南森隆动物保健品有限公司 | Niclosamide or salt oral liquid thereof for livestock and poultry as well as preparation method and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ223200A (en) * | 1988-01-15 | 1989-01-06 | Ancare Distributors | Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier |
| DE69118327T2 (en) * | 1990-11-26 | 1996-08-29 | Bayer Ag | Topically applied lotion containing niclosamide |
-
1998
- 1998-05-29 BR BR9810433-0A patent/BR9810433A/en not_active IP Right Cessation
- 1998-05-29 CA CA002293683A patent/CA2293683A1/en not_active Abandoned
- 1998-05-29 CN CN98806135A patent/CN1260718A/en active Pending
- 1998-05-29 AU AU81086/98A patent/AU8108698A/en not_active Abandoned
- 1998-05-29 KR KR19997011121A patent/KR20010013139A/en not_active Application Discontinuation
- 1998-05-29 WO PCT/EP1998/003238 patent/WO1998056390A1/en not_active Application Discontinuation
- 1998-05-29 EP EP98930768A patent/EP0984783A1/en not_active Withdrawn
- 1998-05-29 JP JP50146299A patent/JP2002511074A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1313438C (en) * | 2004-12-24 | 2007-05-02 | 仲恺农业技术学院 | Preparation method of snail killing agent crude medicine niclosamide |
| CN101601670B (en) * | 2009-06-30 | 2014-06-04 | 青岛蔚蓝生物股份有限公司 | Compound niclosamide parasite-expelling tablet used for pet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| BR9810433A (en) | 2000-09-19 |
| WO1998056390A1 (en) | 1998-12-17 |
| KR20010013139A (en) | 2001-02-26 |
| JP2002511074A (en) | 2002-04-09 |
| AU8108698A (en) | 1998-12-30 |
| EP0984783A1 (en) | 2000-03-15 |
| CA2293683A1 (en) | 1998-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Leaner et al. | Methylmercury accumulation and fluxes across the intestine of channel catfish, Ictalurus punctatus | |
| DE60019116T2 (en) | NEW OMEPRAZOLE AND (S) -OMEPRAZOLE COMPOSITION | |
| FI67390C (en) | FOERFARANDE FOER FRAMSTAELLNING AV EN INKLUSIONSKOMPLEX AV N- (1-PHENYLETHYL) -3,3-DIPHENYLPROPYLAMINE ELLER DESS HYDROCHLORIDES WITH CYCLODEXTRIN | |
| Sachs et al. | Acid, protons and Helicobacter pylori. | |
| CN1260718A (en) | Antithelmintic compositions | |
| RU2005135433A (en) | SUCTION AMPLIFIERS, SUCH AS VNT, VNA OR PROPYLGALLATE | |
| WO2000019999A1 (en) | Fulvic acid and its use in the treatment of various conditions | |
| DE2710327A1 (en) | CARCINOSTATIC AGENT | |
| LT3119B (en) | Pharmaceutical composition and process for the preparation thereof | |
| Elema et al. | Bioavailability of flumequine after oral administration to Atlantic salmon (Salmo salar L.) | |
| CA3009332A1 (en) | Pharmaceutical formulations for treating kidney stones and methods for fabricating and using thereof | |
| FI78615C (en) | FOERFARANDE FOER FRAMSTAELLNING AV ETT KOMPLEX AV KARRAGENAN OCH ANVAENDNINGEN AV KARRAGENAN SOM KOMPLEXBILDANDE MEDEL FOER EMEPRON. | |
| WO2009082267A1 (en) | MEDICINAL AGENT FOR ANTI-Helicobacter THERAPY | |
| WO2008075979A2 (en) | Tablet formulation | |
| EP0024023B1 (en) | Antimycotic agents with enhanced release of the active ingredients | |
| US2841526A (en) | Fatty acid-resin adsorption product | |
| Horsberg et al. | Tissue distribution of 14C-diflubenzuron in Atlantic salmon (Salmo salar) | |
| KR0139442B1 (en) | Method for cultivating bean sprouts and green bean sprouts | |
| CN101450059A (en) | Anthelmintic agent and preparation method thereof | |
| Pollet et al. | The pharmacokinetics of chlortetracycline orally administered to turkeys: influence of citric acid and Pasteurella multocida infection | |
| GB2143732A (en) | Homocarnosine for antitumor formulation | |
| EP2914262B1 (en) | A method of managing urolithiasis and related urological disorders | |
| GB2195082A (en) | Veterinary solutions of thiamphenicol | |
| WO2000078149A1 (en) | Anthelmintic compositions | |
| TWI248366B (en) | Pharmaceutical composition containing radioiodine-labeled 5-iodo-2'-deoxyuridine and preparation thereof for remaining in hepatoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1029053 Country of ref document: HK |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1070978 Country of ref document: HK |